News Sentiment

ESPR sentiment intelligence

Esperion Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 47 Balanced news tone 49 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 3.18 Week of 10 Jul 2026
Weighted tone 47/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

76/100 classification confidence.

Company focus 49

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+0.6% over one week, +1.0% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Neutral

Wasatch Advisors reports 0.7% Esperion Therapeutics (ESPR) stake

Market Reaction

Balanced read

50/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 76/100 classification
One-week reaction 0.6% Price digesting
Trend fit Trend inactive 1.0% over four weeks
Fair value 45.2% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 8
Neutral 31
Negative 10

Relevance

Why the article matched

Direct first
Direct company coverage 49
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 15
TradingView 8
www.marketscreener.com 4
Stocktwits 3
GlobeNewswire 3
Moomoo 2
Market source 2
simplywall.st 2

Event Lens

What the news is about

Classified themes
Market update 23
Deals and strategy 13
Earnings 6
Analyst action 4
Balance sheet 1
Guidance 1
Macro sensitivity 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-49 of 49
TradingView Direct company coverage

Price to earnings forward of Esperion Therapeutics, Inc. – NASDAQ:ESPR

The article focuses on the "Price to earnings forward" metric for Esperion Therapeutics, Inc. (NASDAQ: ESPR). It briefly presents this specific financial data point within a larger financial platform context, implying it's a key piece of information for investors. However, no act

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 08:10
Source
TradingView
TradingView Direct company coverage

Esperion Therapeutics, Inc. Actuals & Estimates (DUS:0ET)

This article provides an overview of Esperion Therapeutics, Inc. (0ET) on the Dusseldorf Stock Exchange, including its financial actuals and analyst estimates. It covers key financial metrics like earnings, revenue, net income, and EBITDA, as well as stock performance data and an

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 07:10
Source
TradingView